Gerresheimer Ag · XETR:GXI
Gerresheimer — Q2 2022 Earnings Presentation
28 slides from Gerresheimer's earnings presentation, Jul 13, 2022
Slide 1: Q2 2022 Results Presentation
Q2 2022 Results Presentation Dietmar Siemssen, CEO Dr. Bernd Metzner, CFO Duesseldorf, July 13, 2022
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Strong Growth Momentum Continues
Strong Growth Momentum Continues CEO Dietmar Siemssen
Slide 4: Transforming Gerresheimer into a growth company
Transforming Gerresheimer into a growth company as innovation leader, solution provider and system integrator. 201 5
Slide 5: Double-Digit Organic Revenue Growth
Double-Digit Organic Revenue Growth Strong Momentum Continues Double-Digit Growth: High Value Solutions Inflation successfully Org. revenue growth Adj. EBITDA (EUR m): +13.7% managed +13.0% +5.1% (FXN) Revenues for ELITE & Adj. EPS: RTF vials doubled Guidance confirmed +0.8% (FXN) 5 07/13/2022 Q2 20
Slide 6: Long-Term Agreements Offer Unique Market Position
Long-Term Agreements Offer Unique Market Position Comments on the Gas Supply Situation Long-term supply German government actions to agreements in place stabilize energy markets Diversified and long-term supply German government sets up protective agreements provide unique shield for energy companie
Slide 7: formula G Roll-out Successfully Progressing
formula G Roll-out Successfully Progressing Strategic Highlights Q2 2022 Profitable Fully integrated Growth: solutions: Another Becoming the leading Double-Digit quarter Solutions Provider & System Integrator Strong Pricing EcoVadis High Value Add Power: Sustainability Rating: Investments: Resilient
Slide 8: Integrated Solutions Across the Value Chain
Integrated Solutions Across the Value Chain Building on our Long-term Expertise API Drug Drug Customer Invention Formulation Manufacturing Drug Development Fill & Marketing & Process Finish Sales Value Added Systems & Washing & Patient Solutions Sterilization Adherence & Physician Support Containmen
Slide 9: Partnering: Key to Expanding our Solutions Offering
Partnering: Key to Expanding our Solutions Offering Broadening our Offering With New Partnerships Some important examples: Focus on Customers: Gx Biological Jointly developing next generation Sustainability Solutions solutions Focus on Strategic BIOLOGICS Customer Partnerships: Expanding expertise f
Slide 10: Financials
Financials CFO Dr. Bernd Metzner
Slide 11: Profitable Growth: Another Double-Digit Quarter
Profitable Growth: Another Double-Digit Quarter Operational View on KPIs Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) organic growth yoy: 13.0% organic growth yoy: 5.1% organic growth yoy: 0.8% 445 90 1,34 1,28 82 377 427 82 87 1.29 1.30 378 Q2 2021 Q2 2022 Q2 2021 Q2 2022 Q2 2021 Q2
Slide 12: Strong Pricing Power
Strong Pricing Power Q2 2022 Revenue Growth Reconciliation Focus on Q2 2022: Focus on H1 2022: ~13% ~16% ~2% ~2-3% ~5% ~6% ~5% ~8% Q2 2022 Contractual Sustainable Q2 2022 H1 2022 Contractual Sustainable H1 2022 org. revenue pass-through price increases revenue growth org. revenue pass-through price
Slide 13: Solid Divisional Performance in Q2 2022
Solid Divisional Performance in Q2 2022 Q2 2022: Divisional Performance and Highlights Organic yoy & margin In EUR m Revenues Adj. EBITDA High-Single Digit Organic Growth +8.0% -4.2% 228 — Strong growth based on volume, price and pass-through 202 53 53 — Comparing a strong comparable period, syringe
Slide 14: Strong Investments Into Profitable Growth
Strong Investments Into Profitable Growth Cash Flow and Financial Debt Q2 2022 Q2 2021 Change In EUR m Comments Adjusted EBITDA 90.1 81.9 8.2 Significantly improved earnings Higher NWC due to strong topline growth as well as Change in net working capital -50.2 -32.6 -17.6 safety stock Net interest p
Slide 15: Successful Refinancing of Promissory Loans
Successful Refinancing of Promissory Loans Structured Two-Step-Approach Now Implemented Maturity Profile Promissory loans of EUR 306m In EUR m successfully refinanced in a two-step 551 approach: Promissory loans 75 RCF ▪ (1) Issuance of a promissory loan of 150m EUR in November 2021 306 ▪ (2) Additi
Slide 16: Outlook
Outlook CEO Dietmar Siemssen
Slide 17: Transforming Gerresheimer into a growth company
Transforming Gerresheimer into a growth company as innovation leader, solution provider and system integrator. 2022 201 5
Slide 18: Guidance Confirmed
Guidance Confirmed Continued Acceleration in 2022 Group level guidance (FXN) focused on three key drivers of shareholder value Adj. EBITDA / Revenue Adj. EPS Margin High High FY 2022 > 10% single-digit single-digit growth growth High Mid-term 23-25% single-digit (margin) ≥ 10% growth 18 07/13/2022 Q
Slide 19: Appendix
Appendix 19 07/13/2022 Q2 2022 Earnings Presentation
Slide 20: Financial Calendar
Financial Calendar Publication 3rd Capital Markets Day Publication Financial Publication 1st Quarter Results 2022 2022 Year 2022 Results Quarter Results 2023 October February April December 12, 2022 23, 2023 6, 2023 20 07/13/2022 Q2 2022 Earnings Presentation
Slide 21: Q2 Revenue & Organic Growth Reconciliation
Q2 Revenue & Organic Growth Reconciliation (1 of 4) in EUR m organic growth 17,4 444.6 +13.0% 427.3 0.7 -1.3 33,8 16,1 377.0 378.0 1.0 +8.0% +19.4% Revenue FX Revenue Q2 P&D PPG GAT HQ, Cons. Revenue Q2 FX Revenue Q2 2021 2021 (FXN) 2022 (FXN) Q2 2022 21 07/13/2022 Q2 2022 Earnings Presentation
Slide 22: Q2 EBITDA & Organic Growth Reconciliation
Q2 EBITDA & Organic Growth Reconciliation (2 of 4) in EUR m organic growth & margin 3,4 90.1 +5.1% 86.7 1,0 2,3 82.5 81.9 0.6 3,2 -2.3 -4.2% +8.3% +21.8% +20.3% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA Q2 2021 EBITDA Q2 EBITDA Q2 Q2 2022 2021 (FXN) 2022 (FXN) 22 07/13/2022 Q2 20
Slide 23: H1 Revenue & Organic Growth Reconciliation
H1 Revenue & Organic Growth Reconciliation (3 of 4) in EUR m organic growth +15.7% 25,4 815.4 790.0 1.6 -2.7 65,9 42,6 679.8 682.6 2.7 +20.5% +11.9% Revenue FX Revenue H1 P&D PPG GAT HQ, Cons. Revenue H1 FX Revenue H1 2021 2021 (FXN) 2022 (FXN) H1 2022 23 07/13/2022 Q2 2022 Earnings Presentation
Slide 24: H1 EBITDA & Organic Growth Reconciliation
H1 EBITDA & Organic Growth Reconciliation (4 of 4) in EUR m organic growth & margin 4,3 151.6 +7.3% 2,8 -1.9 147.3 6,2 137.3 2,9 136.1 1.2 +3.5% +9.5% +20.1% +18.6% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA H1 2021 EBITDA H1 EBITDA H1 H1 2022 2021 (FXN) 2022 (FXN) 24 07/13/2022 Q
Slide 25: Strong Investments Into Profitable Growth
Strong Investments Into Profitable Growth Cash Flow and Financial Debt H1 2022 H1 2021 Change In EUR m Comments Adjusted EBITDA 151.6 136.1 15.5 Earnings significantly improved NWC development almost on par to prior year Change in net working capital -91.4 -78.1 -13.3 despite strong revenue growth a
Slide 26: Reconciliation Q2 2022
Reconciliation Q2 2022 Reported and Adjusted Financials Q2 2022 Q2 Org. 2021 growth Comments Adjust- YoY1 In EUR m Reported Adjusted ment Adjusted Adjusted Revenues 444.6 444.6 377.0 13.0% EBITDA 86.7 3.4 90.1 81.9 5.1% Depreciation & -39.1 9.7 -29.4 -24.1 Adjusted for fair value amortization Amorti
Slide 27: Reconciliation H1 2022
Reconciliation H1 2022 Reported and Adjusted Financials H1 2022 Org. H1 2021 growth Comments Adjust- YoY1 In EUR m Reported Adjusted Adjusted ment Adjusted Revenues 815.4 815.4 679.8 15.7% EBITDA 146.1 5.5 151.6 136.1 7.3% Depreciation & -77.3 19.3 -58.1 -47.9 Adjusted for fair value amortization Am
Slide 28: serresheimer
serresheimer innovating for a better life